Molecular Characterization of Clinical Isolates of Human Immunodeficiency Virus Resistant to the Protease Inhibitor Darunavir
- 1 September 2009
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 83 (17) , 8810-8818
Abstract
Darunavir is the most recently approved human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) and is active against many HIV type 1 PR variants resistant to earlier-generation PIs. Darunavir shows a high genetic barrier to resistance development, and virus strains with lower sensitivity to darunavir have a higher number of PI resistance-associated mutations than viruses resistant to other PIs. In this work, we have enzymologically and structurally characterized a number of highly mutated clinically derived PRs with high levels of phenotypic resistance to darunavir. With 18 to 21 amino acid residue changes, the PR variants studied in this work are the most highly mutated HIV PR species ever studied by means of enzyme kinetics and X-ray crystallography. The recombinant proteins showed major defects in substrate binding, while the substrate turnover was less affected. Remarkably, the overall catalytic efficiency of the recombinant PRs (5% that of the wild-type enzyme) is still sufficient to support polyprotein processing and particle maturation in the corresponding viruses. The X-ray structures of drug-resistant PRs complexed with darunavir suggest that the impaired inhibitor binding could be explained by change in the PR-inhibitor hydrogen bond pattern in the P2′ binding pocket due to a substantial shift of the aminophenyl moiety of the inhibitor. Recombinant virus phenotypic characterization, enzyme kinetics, and X-ray structural analysis thus help to explain darunavir resistance development in HIV-positive patients.Keywords
This publication has 52 references indexed in Scilit:
- New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitorsCurrent Opinion in HIV and AIDS, 2008
- Enzymatic and structural analysis of the I47A mutation contributing to the reduced susceptibility to HIV protease inhibitor lopinavirProtein Science, 2008
- Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and DarunavirJournal of Molecular Biology, 2008
- Ninety-Nine Is Not Enough: Molecular Characterization of Inhibitor-Resistant Human Immunodeficiency Virus Type 1 Protease Mutants with Insertions in the Flap RegionJournal of Virology, 2008
- Does Restricting Pack Size of Paracetamol (Acetaminophen) Reduce Suicides?PLOS Medicine, 2007
- A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance MechanismPLOS Medicine, 2007
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004
- High Resolution Crystal Structures of HIV-1 Protease with a Potent Non-peptide Inhibitor (UIC-94017) Active Against Multi-drug-resistant Clinical StrainsJournal of Molecular Biology, 2004
- Refinement of Macromolecular Structures by the Maximum-Likelihood MethodActa Crystallographica Section D Structural Biology, 1997
- The CCP4 suite: programs for protein crystallographyActa Crystallographica Section D Structural Biology, 1994